REGENXBIO stock reports durable gene therapy data from Phase II
REGENXBIO reported durable three-year data from its Phase II ALTITUDE study for diabetic retinopathy, showing a 60% response rate in Dose Level 3 participants. The company also surpassed Q2 revenue and EPS expectations, though analysts still forecast a full-year loss. Despite a "Moderate Buy" consensus and a significantly higher average price target, the stock remains well below its 52-week high.
(RGNX) Price Dynamics and Execution-Aware Positioning
The article analyzes Regenxbio Inc. (NASDAQ: RGNX) stock dynamics, noting strong near-term sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and presents an exceptional short setup with a significant risk-reward ratio. The analysis, generated by AI models, provides institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Net income before discontinued operations of REGENXBIO, Inc. – HAN:RB0
This article provides financial data for REGENXBIO, Inc. (RB0) on the Hannover Stock Exchange, specifically focusing on its net income before discontinued operations. It indicates the market is currently closed with no trades, and the content is a data point provided by FactSet.
ETFs Investing in REGENXBIO, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold REGENXBIO, Inc. (RB0) stocks. The list provides detailed information for each ETF, including market value, weight of RB0 in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. It serves as a resource for investors interested in REGENXBIO, Inc. through diversified ETF portfolios.
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $21
H.C. Wainwright has reiterated its Buy rating for Regenxbio (RGNX.US), maintaining a target price of $21. This indicates continued confidence from the analyst firm in the company's stock performance and future prospects.
Weekly Recap: REGENXBIO and UPenn settlement and $39M payment to Regenxbio
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) settled patent suits with REGENXBIO and UPenn by paying $39 million. This settlement secures releases and AAVrh74/ELEVIDYS covenants, dismisses litigation, and ensures Sarepta's freedom to operate. Sarepta will also present new efficacy and safety data for ELEVIDYS at upcoming medical conferences.
REGENXBIO reports three-year ALTITUDE DRSS data
REGENXBIO Inc. reported new three-year follow-up data from its ALTITUDE trial, showing that six out of ten higher-dose participants experienced a significant improvement in diabetic retinopathy severity. This data supports the ongoing Phase IIb/III NAAVIGATE trial, which is testing the gene therapy sura-vec against a sham control. The company expects topline results from its ATMOSPHERE and ASCENT trials for wet age-related macular degeneration in Q4 2026 and projects a cash runway into Q4 2027.
REGENXBIO reports three-year sura-vec Phase II results
REGENXBIO (NASDAQ:RGNX) announced positive three-year Phase II results from its ALTITUDE clinical trial for investigational gene therapy sura-vec in non-proliferative diabetic retinopathy. The data showed that 60% of participants, at the highest dose, achieved a significant improvement in diabetic retinopathy severity without further treatment and with no new safety signals or intraocular inflammation observed. This suggests sura-vec could be a promising single-administration treatment for NPDR.
REGENXBIO and Sarepta Resolve ELEVIDYS Patent Litigation with $39 Million Settlement
REGENXBIO Inc. and Sarepta Therapeutics, along with Catalent, Inc. and the University of Pennsylvania, have settled their patent infringement litigation concerning the gene therapy product ELEVIDYS. Sarepta will pay REGENXBIO $39.0 million, and all related patent infringement claims regarding specific patents will be terminated. The agreement also includes a covenant not to sue Sarepta for future claims related to AAVrh74-based capsid gene therapy products, including ELEVIDYS, under the specified patents.
Certain Warrants of REGENXBIO Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2026.
Certain warrants of REGENXBIO Inc. are under a lock-up agreement that will end on September 15, 2026. This lock-up period, which started on July 16, 2026, prevents company directors, officers, and affiliates from selling or transferring common stock or related securities without consent from the underwriters. This restriction is standard practice to stabilize the stock price after certain corporate actions.
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. announced its participation in two upcoming investor conferences: the Baird 2026 Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Both events will feature fireside chats held in New York, NY on September 15 and September 16, 2026, respectively. Webcasts of these events will be available on REGENXBIO's investor relations website.
REGENXBIO to present at two major healthcare investor conferences in September 2026
REGENXBIO Inc., a biotechnology company, will participate in the Baird 2026 Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in September 2026. The company will host fireside chats on September 15 and 16, 2026, to discuss its progress in late-stage gene therapy treatments for rare and retinal diseases. These presentations underscore REGENXBIO's commitment to investor engagement and showcasing its pipeline advancements.
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming investor conferences: the Baird 2026 Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Both events will feature fireside chats held in New York, NY on September 15 and September 16, 2026, respectively. Live webcasts and archived replays will be available on the Investors section of REGENXBIO's website.
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
Regenxbio's gene therapy, RGX-121, for Hunter syndrome has encountered another FDA setback due to clinical hold after spinal scan abnormalities were found in treated participants, though patients remained asymptomatic. This incident adds to previous regulatory hurdles, including a rejection earlier in 2026 over trial design concerns. The company must now address both the imaging findings and past issues before any potential resubmission for approval.
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting
REGENXBIO Inc.'s CFO, Mitchell Chan, reported a tax-driven share withholding on September 1, 2026. This transaction involved the disposition of 4,902 common stock shares, valued at $9.32 each, to cover tax obligations from vested restricted stock units granted in September 2024. Following the withholding, Chan directly holds 122,815 shares of the company's common stock.
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing
This article analyzes Regenxbio Inc. (RGNX) and its impact on rotational strategy timing, highlighting a mid-channel oscillation pattern and a significant 113.0:1 risk-reward setup. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths and support/resistance levels for RGNX.
Regenxbio director Ciongoli buys $949,381 in RGNX stock
Gregory Austin Ciongoli, a director at REGENXBIO Inc. (NASDAQ:RGNX), recently acquired common stock worth $949,381 through open-market purchases and received additional shares and stock options as part of his compensation. These transactions occurred amidst a stock price dip, with InvestingPro analysis suggesting the company remains undervalued. The news follows a clinical hold by the FDA on REGENXBIO's investigational gene therapy RGX-121, leading to revised price targets from analysts.
REGENXBIO Director Gregory Ciongoli Discloses Multiple Stock Purchases and Option Grant in August 2026
REGENXBIO Inc. Director Gregory Austin Ciongoli reported multiple equity transactions between August 25 and August 27, 2026, via a Form 4 filing. These transactions include the grant of 15,432 Restricted Stock Units, two open-market purchases totaling 102,603 shares, and an option grant to buy 69,609 shares. Following these activities, Ciongoli's direct ownership in REGENXBIO now stands at 118,035 common shares and 69,609 stock options.
People on the Move: Greg Ciongoli Joins REGENXBIO’s Board of Directors
Greg Ciongoli has been appointed to REGENXBIO's Board of Directors, effective August 25, 2026, coinciding with the retirement of two independent directors. Ciongoli brings extensive financial and strategic expertise from his roles at Adiumentum Capital Management and The Baupost Group, as well as prior board experience in the biotechnology sector. REGENXBIO, a biotechnology company focused on gene therapy, aims to leverage Ciongoli's experience to advance its late-stage pipeline for rare and retinal diseases.
Regenxbio stock surges on director share purchases
Regenxbio Inc. shares rose significantly after director Gregory Austin Ciongoli purchased over 100,000 common shares in open-market transactions, totaling over $950,000. Ciongoli also received restricted stock units and stock options as part of his compensation. These substantial insider purchases often indicate confidence in the company's future prospects.
REGENXBIO (RGNX) grants $550K equity to new board hire
REGENXBIO Inc. (RGNX) has appointed Gregory Ciongoli as an independent Class II director, effective August 25, 2026, granting him an initial equity award valued at $550,000, split between stock options and restricted stock units. This change is part of the company's strategic board succession planning as it prepares for commercial growth in gene therapies. Concurrently, directors Jean Bennett, M.D., Ph.D. and A.N. “Jerry” Karabelas, Ph.D. resigned, reducing the board size to nine members.
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Johnson Fistel, PLLP is investigating potential claims against REGENXBIO Inc. (RGNX) officers and directors for alleged breaches of fiduciary duty. The investigation focuses on shareholders who continuously held RGNX shares prior to February 9, 2022, following allegations of misleading statements regarding the RGX-111 clinical trial and undisclosed safety risks, including a central nervous system tumor in a trial participant. The law firm is offering these shareholders an opportunity to seek corporate governance reforms and financial recovery without personal cost.
RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy
REGENXBIO (RGNX) stock dropped 25% after the FDA placed a clinical hold on its gene therapy RGX-121 for Hunter syndrome due to spine MRI findings in patients. This setback follows a previous complete response letter from the FDA regarding the treatment. While RGX-121's future is uncertain, REGENXBIO has other pipeline candidates like RGX-202 for Duchenne muscular dystrophy and ABBV-RGX-314 for wet age-related macular degeneration, which could be near-term catalysts.
Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity (NASDAQ:RGNX)
Regenxbio (RGNX) is presented as a 'risky buy' due to its high volatility, recent regulatory setbacks, and significant upcoming catalysts. The company faces a clinical hold on RGX-121 for Hunter Syndrome, which impacts potential milestone payments, but has a cash runway until Q4 2027. Major binary catalysts include pivotal data for an eye disease program and a BLA submission for RGX-202, offering exposure to late-stage gene therapy assets in large markets, though bankruptcy risk remains if the pipeline fails.
REGENXBIO Adds Greg Ciongoli to Board Ahead of Commercial Expansion
REGENXBIO Inc. has appointed biotechnology investor Greg Ciongoli to its Board of Directors, effective August 25, 2026, as the company prepares to transition into a global commercial organization. Ciongoli brings extensive experience in biotechnology investing, capital allocation, and corporate strategy, which will be crucial as REGENXBIO advances its late-stage gene therapy programs. This appointment is part of an ongoing board succession, with independent directors Jerry Karabelas and Jean Bennett retiring, aiming to balance scientific, clinical, commercial, and capital markets expertise for the company's next growth phase.
Regenxbio appoints Greg Ciongoli to board of directors
REGENXBIO Inc. has announced the appointment of Greg Ciongoli to its board of directors, effective immediately. Ciongoli is the founder of Adiumentum Capital Management and previously served as a partner at The Baupost Group. His appointment coincides with the retirement of two long-serving independent directors, Jerry Karabelas and Jean Bennett, as REGENXBIO continues its strategic succession planning for future growth.
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
REGENXBIO Inc. has appointed Greg Ciongoli to its Board of Directors, effective August 25, 2026. Mr. Ciongoli brings extensive experience in biotechnology investing, capital allocation, and corporate strategy to support the company's growth as it prepares to become a global commercial organization with multiple upcoming gene therapy catalysts. Concurrently, long-serving independent directors Jerry Karabelas, Ph.D., and Jean Bennett, M.D., Ph.D., have retired from the Board.
Regenxbio’s Second Clinical Hold in Eight Months Exposes a Safety Monitoring System That Was Never Rebuilt After the First One
Regenxbio's gene therapy RGX-121 for Hunter syndrome has been placed on a second clinical hold by the FDA due to spine MRI abnormalities found in five additional patients, exposing a failure in the company's safety monitoring system. This comes after an initial hold in January 2026 and a Complete Response Letter in February citing insufficient evidence of effectiveness. The article argues that the FDA has lost confidence in Regenxbio's ability to monitor patient safety, highlighting the critical need for robust, pre-specified safety protocols, especially in rare pediatric disease trials where every patient and month matters.
REGENXBIO says FDA places RGX-121 on clinical hold; BLA resubmission not expected soon
REGENXBIO announced that the FDA has placed a clinical hold on its RGX-121 program due to asymptomatic spine MRI findings in five participants during a Phase I/II/III MPS II trial. Although the participants remain clinically well and the findings are deemed likely benign, the company does not expect to resubmit the RGX-121 Biologics License Application (BLA) in the near term. REGENXBIO will incorporate FDA feedback and longer-term follow-up into its next steps.
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
The FDA has placed a clinical hold on Regenxbio's experimental gene therapy, RGX-121, for Hunter Syndrome after spinal scans revealed abnormalities in five study participants, causing the company's shares to drop significantly. This marks another regulatory setback for Regenxbio, following a prior FDA refusal to approve RGX-121 due to trial design concerns. Despite the findings, the patients remain asymptomatic, and the company will review further data before deciding next steps.
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold
Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) after the FDA placed its RGX-121 gene therapy program on clinical hold. This hold was initiated due to asymptomatic findings in spine MRI scans of clinical trial participants, following an earlier hold on its RGX-111 program. REGENXBIO does not expect to resubmit its biologics license application for RGX-121 in the near term, prompting the investigation into potential investor losses.
Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
The FDA has placed a second clinical hold this year on Regenxbio's gene therapy, RGX-121, for Hunter syndrome due to safety concerns. Investigators found masses on the spines of five trial participants, though Regenxbio states these are "likely" benign and patients remain asymptomatic. This setback has led Regenxbio to delay its resubmission for accelerated approval, causing a significant drop in its shares.
Spinal MRI findings trigger FDA hold, derail RegenxBio’s RGX-121 filing
RegenxBio's planned Biologics License Application (BLA) resubmission for its gene therapy Navsunli (RGX-121) has been indefinitely delayed due to a clinical hold imposed by the FDA. The hold was triggered by asymptomatic spinal MRI findings, specifically small nodules or cystic masses, in five participants of the CAMPSIITE study. This development follows a previous Complete Response Letter and subsequent alignment with the FDA on an accelerated approval pathway, which is now suspended.
REGENXBIO’s Hunter syndrome gene therapy hit by FDA hold, stymieing resubmission plans
The FDA has placed a clinical hold on REGENXBIO's Hunter syndrome gene therapy, RGX-121, after small nodules or cystic masses were found in the spines of five patients in a clinical trial. This development has forced REGENXBIO to halt its plans for near-term resubmission of the biologics license application, which had previously been rejected in February but was recently deemed sufficient for an accelerated approval pathway. The company's stock fell 22% in premarket trading following the news.
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold
Regenxbio's stock is down after the FDA placed a clinical hold on its gene therapy RGX-121 for Hunter Syndrome. The hold follows the discovery of asymptomatic spine MRI findings in five participants, although investigators consider these findings likely benign and nonserious. The company does not expect to resubmit its Biologics License Application for RGX-121 in the near term.
REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121
REGENXBIO Inc. (NASDAQ:RGNX) shares plummeted 35% after the FDA placed a clinical hold on its gene therapy RGX-121 for Hunter Syndrome due to asymptomatic findings in spine MRI scans of five participants. This regulatory setback means REGENXBIO no longer expects to resubmit the Biologics License Application for RGX-121 in the near term. Despite this, the company's Duchenne muscular dystrophy and retinal disease programs remain on track, with key milestones expected in the current and fourth quarters.
REGENXBIO stock tumbles after FDA clinical hold on MPS II therapy
REGENXBIO Inc. shares plummeted 35% after the FDA placed a clinical hold on its gene therapy RGX-121 for Hunter Syndrome due to asymptomatic spine MRI findings in five participants. The company does not expect to resubmit the Biologics License Application for RGX-121 soon but will focus on its Duchenne and retinal disease candidates, with plans to submit a BLA for Duchenne this quarter and announce wet AMD data in Q4.
FDA pauses Regenxbio gene therapy trial again due to safety concerns
The FDA has once again halted trials for Regenxbio's gene therapy for Hunter syndrome (MPS II) after five patients developed small masses on their spines. This follows a previous incident seven months prior where another patient receiving a similar therapy for MPS I developed a brain tumor, marking the first confirmed tumor linked to AAV gene therapy. The company stated the patients with spinal masses are not experiencing symptoms.
Five patients had spine MRI findings; FDA put the gene therapy on hold
REGENXBIO (RGNX) announced that the FDA has placed a clinical hold on its gene therapy, RGX-121, for MPS II due to asymptomatic spine MRI findings in five participants. While the company does not expect to resubmit the Biologics License Application (BLA) in the near term for RGX-121, the affected patients remain clinically well. REGENXBIO will now focus on its Duchenne and retinal disease candidates, with a Duchenne BLA submission planned this quarter and wet AMD data in Q4.
FDA Places New Clinical Hold On RGX-121 for Hunter Syndrome
The FDA has placed a new clinical hold on REGENXBIO's gene therapy RGX-121 for Hunter syndrome after asymptomatic spine MRI findings were observed in five trial participants, marking the second regulatory setback this year for the therapy. These findings, described as small nodules or cystic masses, were deemed nonserious and likely benign by investigators, and all affected patients remain clinically stable. REGENXBIO does not expect to resubmit the Biologics License Application (BLA) for RGX-121 in the near term, shifting focus to other Duchenne and retinal disease candidates.
Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings
The FDA has placed a clinical hold on Regenxbio's gene therapy candidate RGX-121 due to asymptomatic spine MRI findings, disrupting the biotech's plans to refile for its approval. This latest development follows an earlier hold in January, prompting enhanced monitoring which revealed small nodules or cystic masses in the spines of five trial participants. Despite investigators deeming these findings non-serious and likely benign, Regenxbio has delayed its refiling, causing its share price to drop significantly.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds
Bronstein, Gewirtz and Grossman, LLC has issued an investor alert for REGENXBIO Inc. (NASDAQ: RGNX), announcing a class action lawsuit filed against the company and its officers. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its RGX-111 gene therapy for MPS I, specifically overstating its efficacy and safety profile during the Class Period between February 9, 2022, and January 27, 2026. Investors who suffered losses are encouraged to contact the firm to join the lawsuit and request to be appointed lead plaintiff by April 14, 2026.
Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX
Walleye Capital LLC has invested $2.44 million in REGENXBIO Inc. by acquiring 203,726 shares during the second quarter, making them one of many institutional investors in the company. REGENXBIO exceeded analyst expectations with its recent earnings report, posting $0.43 EPS and $108.02 million in revenue. Despite some recent analyst downgrades and price target reductions, the stock generally maintains a "Moderate Buy" rating with a consensus price target of $23.73.
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research
Zacks Research has upgraded REGENXBIO (NASDAQ:RGNX) from a "strong sell" to a "hold" rating. This upgrade comes as the biotechnology company exceeded revenue and EPS estimates in its latest quarterly report, though it remains unprofitable. Institutional investors hold a significant portion of the company's shares, with BlackRock Inc. recently acquiring a new stake.
Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX
Assenagon Asset Management S.A. significantly reduced its stake in REGENXBIO Inc. by 82.7% in the second quarter, now holding 169,279 shares valued at $2.03 million. Despite this, institutional investors still own a substantial 88.08% of the company. REGENXBIO recently surpassed analyst estimates for quarterly revenue and earnings, though it remains unprofitable with a negative net margin.
(RGNX) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The analysis also includes a multi-timeframe signal breakdown for near-term, mid-term, and long-term horizons, suggesting choppy conditions for the stock.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged federal securities law violations. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding the development and commercialization of RGX‑111 for severe MPS I. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the lawsuit and have until April 14, 2026, to seek lead plaintiff status.
H.C. Wainwright lowers Regenxbio stock price target on equity offering
H.C. Wainwright has lowered its price target for Regenxbio (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's public offering of common stock in July 2026. This adjustment comes as Regenxbio reported Q2 2026 revenue of $108 million, including a significant milestone payment from AbbVie, and plans to submit a Biologics License Application for RGX-202 in Duchenne muscular dystrophy. Despite a recent downgrade by Barclays to Equalweight, the company's financial position has improved, extending its runway into Q4 2027.
H.C. Wainwright lowers Regenxbio stock price target on equity offering
H.C. Wainwright has lowered its price target for Regenxbio Inc. (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's public offering of common stock in July 2026. Despite the revised target, Regenxbio reported strong second-quarter 2026 results, including $108.0 million in revenue and $22.7 million in net income, bolstered by a significant milestone payment from AbbVie. The biotech firm is also progressing with its Biologics License Application for RGX-202 in Duchenne muscular dystrophy, aiming for accelerated approval in the second half of 2027.
H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com
H.C. Wainwright has reduced its price target for Regenxbio Inc. (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's July 2026 public stock offering. Regenxbio reported strong second-quarter 2026 revenues and net income, including a significant milestone payment from AbbVie. The company is also progressing with its Biologics License Application for RGX-202 in Duchenne muscular dystrophy, targeting potential accelerated approval in late 2027, despite a recent downgrade from Barclays due to regulatory uncertainty.
